Loading...
•
Dec 31, 2022
Moleculin Q4 2022 Earnings Report
Reported financial results for the full year 2022 and provided a pipeline update.
Key Takeaways
Moleculin Biotech reported its full year 2022 financial results, highlighting progress in clinical and preclinical development programs and sufficient capital to fund operations into the third quarter of 2024.
Announced the publication of data evaluating Annamycin's performance as an anthracycline in the European Journal of Cancer.
Received approval in Italy and dosed first subjects for Phase 1/2 trial evaluating Annamycin in combination with cytarabine for AML treatment.
Announced final topline successful safety data and reported 80% overall response rate in final cohort from the European Phase 1 trial evaluating Annamycin as a single agent treatment of Refractory AML.
Granted Fast Track Designation from the FDA of WP1122 for the treatment of Glioblastoma Multiforme (GBM).
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...